BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 36935845)

  • 1. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records.
    Kislaya I; Peralta-Santos A; Borges V; Vieira L; Sousa C; Ferreira B; Pelerito A; Gomes JP; Leite PP; Nunes B; ; Machado A; Rodrigues AP; Peixoto VR; Casaca P; Fernandes E; Rodrigues E; Ferreira R; Isidro J; Pinto M; Duarte S; Santos D; Meneses L; Almeida JP; Matias A; Freire S; Grilo T
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13121. PubMed ID: 36935845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
    Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
    Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Korves C; Izurieta HS; Smith J; Zwain GM; Powell EI; Balajee A; Ryder KM; Young-Xu Y
    Vaccine; 2022 Aug; 40(33):4742-4747. PubMed ID: 35773122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Jan; 29(1):101-106. PubMed ID: 36028091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    Lind ML; Robertson AJ; Silva J; Warner F; Coppi AC; Price N; Duckwall C; Sosensky P; Di Giuseppe EC; Borg R; Fofana MO; Ranzani OT; Dean NE; Andrews JR; Croda J; Iwasaki A; Cummings DAT; Ko AI; Hitchings MDT; Schulz WL
    PLoS Med; 2022 Dec; 19(12):e1004136. PubMed ID: 36454733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
    He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
    Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.
    Andeweg SP; de Gier B; Eggink D; van den Ende C; van Maarseveen N; Ali L; Vlaemynck B; Schepers R; Hahné SJM; Reusken CBEM; de Melker HE; van den Hof S; Knol MJ
    Nat Commun; 2022 Aug; 13(1):4738. PubMed ID: 35961956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.